Nearly two weeks after President Trump’s TrumpRx announcement, Amgen unveiled its own direct-to-consumer (DTC) program, announcing a discounted price for its cholesterol drug, Repatha, at $239 per…
News Oct 3, 2025Even in a crowded week of news, prescription drug pricing remained prominent with President Trump’s announcement of TrumpRx — a new government direct-to-consumer platform — alongside a deal with…
News Sep 26, 2025On Wednesday, P4AD filed its fifth patient-centered amicus brief defending the Medicare Negotiation Program, this time against PhRMA’s appeal to the Fifth Circuit.
News Sep 19, 2025In a unanimous decision, the Third Circuit U.S. Court of Appeals rejected Novartis’ challenge and stood with Medicare negotiation, exactly one week after the same court delivered a similar defeat to…
News Sep 12, 2025P4AD patient advocates from 10 states across the country travelled to D.C. this week to meet with lawmakers on both sides of the aisle.
News Sep 5, 2025Yesterday morning, the U.S. Court of Appeals For The Third Circuit rejected Bristol Myers Squibb (BMS) and Janssen’s challenge to the Medicare Drug Price Negotiation Program.
News Aug 29, 2025It’s been four weeks since Trump sent letters to 17 pharmaceutical companies demanding they align prescription drug prices with other high income nations, and Big Pharma is working hard to avoid any…
News Aug 23, 2025AstraZeneca, Bristol Myers Squibb, Eli Lilly, and Merck have launched a new lobbying group aimed squarely at undermining the popular Medicare Drug Price Negotiation Program — the most significant…
News Aug 15, 2025Fierce Pharma’s latest ranking of the most expensive drugs in the U.S. underscores the rapid escalation in launch prices, driven primarily by gene therapies priced between $2.2 million and $4.25 million per dose.
News Aug 8, 2025This week saw three blows to pharma’s multi-million dollar legal campaign against the Medicare Negotiation Program.
1:49 · Watch on YouTube
3:50 · Watch on YouTube
0:51 · Watch on YouTube
